logo
Early results from major clinical trial show healthy lifestyle slows cognitive decline

Early results from major clinical trial show healthy lifestyle slows cognitive decline

NBC News5 days ago
Phyllis Jones wakes up every morning to work up a sweat in countries all over the world, 'and even sometimes on the moon,' she said, thanks to her favorite workout gadget, a virtual reality headset.
Her focus on exercise is light-years away from where Jones, 66, of Aurora, Illinois, was just a few years ago. She had prediabetes, and her cholesterol and blood pressure levels were inching up.
She was totally sedentary after falling into deep depression. 'I was in bed. I didn't care at all. I was just spiraling,' Jones said.
She was probably also destined to lose her ability to think clearly.
Jones' mother and grandmother died of vascular dementia, a condition that occurs when the body can't pump enough blood to the brain. Other family members had the disease, too.
'Watching two generations suffer made me determined to break the cycle for myself,' Jones said. 'I'm not that person anymore.'
Four years ago, Jones joined a major clinical trial, called U.S. POINTER, that aimed to figure out how older adults at high risk for dementia can stay healthier longer.
Half of the more than 2,000 participants were given advice on a healthy lifestyle, including diet and exercise. The other half was thrust into a structured, team-based program that gave participants goals to transform their lifestyles. The program included meeting with experts and other participants regularly, as well as brain exercises and aerobics classes. Participants were instructed to follow the MIND diet, which trades processed foods for whole grains, fruits, leafy greens and other vegetables.
The researchers evaluated cognitive function by measuring memory, the ability to focus while juggling multiple tasks, and how quickly people interpreted and responded to information.
After two years, both groups showed progress. But people in the structured group saw greater benefits.
'Our conservative estimate shows that, relative to the self-guided group, the structured group performed at a level comparable to adults who were one to two years younger in age,' said Laura Baker, lead researcher and a gerontology professor at Wake Forest University School of Medicine and Advocate Health in Winston-Salem, North Carolina.
'This is what's giving folks additional resilience against cognitive decline,' she said.
Greater support and accountability in the structured group were key benefits.
'We're going to tell you what to do, but we're also going to help you get there, and we're going to work with you as a partner to meet you where you are,' Baker said during a news briefing about the findings Monday at the Alzheimer's Association International Conference in Toronto.
The research, published simultaneously in the Journal of the American Medical Association, is the first large-scale randomized controlled trial to show that organized, sustainable lifestyle interventions can have a measurable impact on brain health.
It's an important finding as the nation is on a path to double the number of people living with dementia by 2060. About 10% of Americans over age 65 have been diagnosed with dementia, according to the Centers for Disease Control and Prevention. Nearly 7 million people in the U.S. have Alzheimer's, the most common type of dementia.
While some drugs may slow how quickly dementia develops, there is no cure.
'Some people are scared, thinking there's nothing you can do' to ward off dementia, said Dr. Richard Isaacson, a neurologist and researcher at the Institute for Neurodegenerative Diseases in Florida.
We're not powerless in the fight against cognitive decline.
Dr. Richard Isaacson
The new findings, he said, show that 'we're not powerless in the fight against cognitive decline and Alzheimer's disease.' Isaacson, who formerly directed the Alzheimer's Prevention Clinic at NewYork-Presbyterian/Weill Cornell Medical Center, was not involved with the new research.
This isn't the only study to link lifestyle to a delay in dementia.
Other research presented at the Alzheimer's Association conference Monday found that regular walking can protect the brains of people with a genetic risk for Alzheimer's.
The beauty of lifestyle interventions now proven to help keep cognition sharp is that they can be applied universally, said Rachel Wu, an associate professor of psychology who researches cognition in older adults at the University of California, Riverside.
'There's no downside, no side effects to doing this stuff, except just the time it takes,' Wu said.
POINTER trial researchers also took blood samples and scanned participants' brains, looking for amyloid and tau, proteins associated with Alzheimer's disease that form plaques and tangles in the brain.
Those samples will be included in a future analysis of study participants, said Heather Snyder, a POINTER researcher and senior vice president of medical and scientific relations at the Alzheimer's Association.
'If you have this biology, do you see a better response? Less response?' she said. 'That's the kind of meaningful question we're going to be able to ask with this data.' Additional findings are expected within the year, Snyder said.
Jones is eager to see those results when they're available.
'I don't know what they saw in my brain, but I know I'm a different person,' Jones said. She's lost 30 pounds and is no longer considered prediabetic or a candidate for statins to reduce her cholesterol.
'I'm going to keep moving, eating right, socializing, monitoring my comorbidities,' she said. 'I'm going to take care of myself.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

'A little itch turned out to be skin cancer'
'A little itch turned out to be skin cancer'

Yahoo

time3 hours ago

  • Yahoo

'A little itch turned out to be skin cancer'

Two years ago, Tom Jones noticed a mole on his chest that he "didn't bother with". The head of hospitality in Herm said "it was a little itchy" every so often but otherwise caused him no trouble. A visit to the doctor confirmed it was a melanoma that had grown rapidly under the skin. "Don't think that little itch is nothing because it's what's underneath is the problem, not what's on top," he said. "It came back to haunt me." More news stories for Guernsey Listen to the latest news for Guernsey Mr Jones said he was now a "breast less" after the 4.5 inch melanoma under his right nipple needed to be removed. He said the growth on his chest "changed colour and it began to be quite an annoyance". He got checked over at the hospital and was told it had been there "an awful long time" and it had grown significantly under his skin. An operation which saw the full removal of his right breast. Mr Jones said: "It had been growing quite rapidly underneath the skin, so therefore it wasn't treatable with a small incision, it had to be taken out completely." The melanoma was successfully cut out but Mr Johns said he still goes for regular check-ups. He urged visitors to the island to take responsibility of their safety in the sun. "I'm personally more aware of that than anyone else because I have fallen foul to not protecting myself," he said. "Don't hesitate, get that sun cream on, and if you've got an itch, get it checked. "It's everyone's personal responsibility and it's really important for you to bring some protection with you [to the island]." This story is part of BBC Guernsey's Sun Safety Campaign. Follow BBC Guernsey on X and Facebook and Instagram. Send your story ideas to More on this story Cancer diagnosis after beautician spotted change Wear SPF 50, warns islander with skin cancer How sun-conscious is our culture? Guernsey sun safety imperative, says charity Push for islanders to protect ears in the sun

BrightSpring Health Services, Inc. (BTSG) Q2 Earnings and Revenues Beat Estimates
BrightSpring Health Services, Inc. (BTSG) Q2 Earnings and Revenues Beat Estimates

Yahoo

time20 hours ago

  • Yahoo

BrightSpring Health Services, Inc. (BTSG) Q2 Earnings and Revenues Beat Estimates

BrightSpring Health Services, Inc. (BTSG) came out with quarterly earnings of $0.22 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.1 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +15.79%. A quarter ago, it was expected that this company would post earnings of $0.08 per share when it actually produced earnings of $0.19, delivering a surprise of +137.5%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. BrightSpring Health Services, Inc., which belongs to the Zacks Medical Services industry, posted revenues of $3.15 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 5.40%. This compares to year-ago revenues of $2.73 billion. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. BrightSpring Health Services, Inc. shares have added about 21.3% since the beginning of the year versus the S&P 500's gain of 7.8%. What's Next for BrightSpring Health Services, Inc.? While BrightSpring Health Services, Inc. has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for BrightSpring Health Services, Inc. was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.28 on $3.16 billion in revenues for the coming quarter and $0.90 on $12.29 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Services is currently in the top 35% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, Progyny (PGNY), has yet to report results for the quarter ended June 2025. The results are expected to be released on August 7. This provider of fertility and family building benefits is expected to post quarterly earnings of $0.44 per share in its upcoming report, which represents a year-over-year change of +2.3%. The consensus EPS estimate for the quarter has been revised 4.1% lower over the last 30 days to the current level. Progyny's revenues are expected to be $322.5 million, up 6.1% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report BrightSpring Health Services, Inc. (BTSG) : Free Stock Analysis Report Progyny, Inc. (PGNY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

A Doctor's Plea From a Nation Asleep on Brain Disease
A Doctor's Plea From a Nation Asleep on Brain Disease

Newsweek

timea day ago

  • Newsweek

A Doctor's Plea From a Nation Asleep on Brain Disease

Advocates for ideas and draws conclusions based on the interpretation of facts and data. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. As a physician who once treated pain, I now endure the unimaginable. Amyotrophic lateral sclerosis (ALS) has left me quadriplegic, dependent on a tracheostomy to breathe and a feeding tube to eat. Diagnosed at 35, my career ended abruptly. My family's story reveals the scale of the coming storm—my father battles Alzheimer's, my uncle succumbed to Parkinson's, and my grandmother to Lewy body dementia. We are not outliers; we represent a silent epidemic. Neurodegenerative diseases are surging, yet our nation slumbers, unaware of the devastation ahead. The public's complacency is by design, built on a statistical illusion. ALS, fatal since 1869, exemplifies this peril. With a median survival of 2-3 years, it strikes about 1 in 300 people in their lifetime, which predicts that over 1 million people now alive in the U.S. will succumb to ALS. Yet, under federal law, it is labeled "rare" because that definition is based on prevalence—a static snapshot of how many people are living with a disease at one time. Because ALS kills its victims so quickly, the number of living patients stays below the 200,000-person "rare" threshold. Its very lethality ensures it is never treated like the mainstream public health crisis it is. This paradox obscures a terrifying forecast: a projected 69 percent global increase in ALS cases by 2040. This illusion of rarity perpetuates a deadly inaction that extends to all brain diseases. Alzheimer's already affects over 7 million Americans and is projected to strike nearly 13 million by 2050, costing our economy $384 billion in 2025—and projected to nearly $1 trillion annually by mid-century. Exterior view of the headquarters of the U.S. Food and Drug Administration (FDA). Exterior view of the headquarters of the U.S. Food and Drug Administration (FDA). Getty Images The failure to confront this crisis stems from a Tale of Two Agencies within the Food and Drug Administration (FDA). In 2017, Congress established the Oncology Center of Excellence (OCE), a dynamic hub that has revolutionized cancer treatment, accounting for 85 percent of all accelerated approvals in the last decade. This success is the result of focused will and resources; National Institutes of Health (NIH) funding for cancer has topped $7.2 billion, compared to $2.8 billion for neuroscience. Neurology has no such center. Lacking an institutional home, it is fragmented, slow, and characterized by a risk aversion unthinkable in oncology. This disparity persists because of the tragic nature of these diseases. In the 1980s, ACT UP activists staged "die-ins" to force a reluctant government to fight AIDS. Patients with ALS, Huntington's, or Alzheimer's cannot mount a similar protest—we are physically silenced and immobilized, unable to "seize the FDA." This vulnerability places a unique moral obligation on our leaders to act proactively on behalf of the voiceless. The new FDA leadership now arrives with bold promises of change, posing a question that haunts everyone touched by an untreatable neurological disease: Will this time be different? Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. vows to "sweep away barriers" and to "figure out new ways ... of accelerating approvals for drugs and treatments that treat rare diseases." FDA Commissioner Marty Makary has several times asked why it takes 10 years for a drug to get to market and proposes a "conditional approval" pathway based on a "plausible mechanism." Center for Biologics Evaluation and Research (CBER) Director Vinay Prasad promised to "take action at the first sign of promise for rare diseases." For the ALS community, these words are now a crisis of credibility. In a disease that has a median survival of 2-3 years, we are asking for regulatory flexibility for a treatment that began its Phase 1 trial in 2011 and was granted FDA Fast Track designation in 2014. As a petitioner on the July 3 citizens' petition for a stem cell therapy known as NurOwn, my community has presented the FDA with a clear test. Ultimately, we are seeking accelerated approval based on new, unprecedented survival data from an expanded access program—data that exceeds the extension of survival of many approved cancer therapies. But the initial request is simpler: invite the sponsor to resubmit its application for a full review. Ours is a request for due process to give a voice to the voiceless—the lowest possible bar for the Trump administration to demonstrate its promised flexibility. A clear, bipartisan solution has already failed once. The Neuroscience Center of Excellence Act, introduced in 2021 to replicate oncology's success for brain disease, stalled in committee. It is time for our leaders to find the political will that has been so catastrophically absent. Congress must immediately revive and pass the Neuroscience Center of Excellence Act. The FDA, in turn, must match its leaders' promises with action by granting our petition a review. The science is poised for breakthroughs, but it is being shackled by a broken system. For those of us on a deadline, this is not a policy debate. It is a death sentence. Awaken now, before this silent storm engulfs us all. The voiceless can't wait. Dr. Shahriar Minokadeh, a former anesthesiologist trained at Johns Hopkins and pain management at UC San Diego, types via an eye-gaze device. The views expressed in this article are the writer's own.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store